Canine C-reactive protein in the 21stCentury: Where are we now and where are we going?

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Canine C-reactive protein in the 21stCentury: Where are we now and where are we going?

Dr Vincent Botha

AC/1905/24

Vetnews October 2024

CPD POINT ACCREDITED TO THIS ARTICLE: ONE (1)
PASSRATE: 80%
RETRIES ALLOWED: 3
CPD POINTS EARNED WILL BE UPLOADED TO THE SAVC PORTAL BY SAVA

NOTE:

NON-SAVA MEMBERS WILL BE INVOICED (VIA EMAIL) FOR THIS ARTICLE: R300.00

(ONCE PAYMENT IS RECEIVED, THE CPD POINT WILL BE UPLOADED TO THE SAVC PORTAL)

If you need a CPD certificate for successfully completing this quiz, please forward you request to assistant@sava.co.za

Sign in to Google to save your progress. Learn more

Name and Surname *

SAVC Number *

SAVA Number *

E-mail address *

QUESTION 1

Which of the following are considered the primary functions of acute phase proteins in the innate immune response:

*

1 point

a. Activation of the liver to produce APPS

b. Regulation of inflammation

c. Immunomodulation

d. B + C

e. A + B + C

QUESTION 2

What happens to major, moderate and minor acute phase proteins after tissue damage?

*

1 point

a. They decrease at a proportionate rate

b. They increase at a proportionate rate

c. The remain stable

d. None of the above

e. All of the above

QUESTION 3

Why can the classification of acute phase proteins (APPs) vary in academic settings?

*

1 point

a. Because of differences in statistical analysis

b. Because of differences in research design

c. Because of differences in disease models

d. Because the type of assay used can influence the detectability of the APP

e. Because different laboratories use different assays

QUESTION 4

Which of these is not recognised as a function of C-reactive protein (CRP)?

*

1 point

a. Melioration of opsonization

b. Induction of complement

c. Downregulation of immune response

d. Impeding chemotaxis

e. Induction of cytokines

QUESTION 5

Which of these immunoassays are considered point-of-care (POC) assays:

*

1 point

a. Magnetic binding immunoassay

b. Immunochromatographic assay

c. Immunoturbidometric assay

d. Flow-type immunoassay

e. A + B + D

QUESTION 6

Which of these endings would make the sentence incorrect: CRP is most helpful as a diagnostic tool when used to:

*

1 point

a. Monitor disease progression

b. Prognosticate a patient's likelihood of survival

c. Increase the sensitivity of your diagnostics

d. Monitor response to treatment

e. Help guide clinical decisions

QUESTION 7

If you are presented with a young patient with diarrhoea; which differential would be less likely if the CRP level was 90mg/L:

*

1 point

a. Parvovirus infection

b. Intestinal neoplasia

c. Pancreatitis

d. Inflammatory bowel disease

e. Bacterial enteritis

QUESTION 8

A canine presents with hindlimb ataxia and delayed proprioception. There is no history of trauma and you run a CRP and get a serum level of 200mg/L. Which of these differential diagnoses should be highest on your list:

*

1 point

a. Discospondylitis

b. Intervertebral disc disease

c. Steroid-responsive meningitis arteritis

d. Wobblers disease

e. A + B

QUESTION 9

What is predicted to be a very important step for future development and validation of CRP assays?

*

1 point

a. Increased use of human CRP assays on canine samples

b. The establishment of a universally accepted gold-reference standard assay for CRP

c. The establishment of a human-specific anti-CRP antibody

d. The development of assays that can measure extremely high levels of CRP

e. C + D

QUESTION 10

Which of these statements is incorrect:

*

1 point

a. CRP is a highly sensitive diagnostic tool

b. CRP is a highly specific diagnostic tool

c. CRP gives real-time information regarding the clinical state of a patient

d. CRP helps to detect and quantify the presence of inflammation

e. CRP is both sensitive and specific

Submit

Clear form

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. - Terms of Service - Privacy Policy

Does this form look suspicious? Report